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Several biomarkers have been proposed as useful parameters to better specify the prog-
nosis or to delineate new target therapy strategies for glioblastoma patients. MicroRNAs
could represent putative target molecules, considering their role in tumorigenesis, cancer
progression and their specific tissue expression. Although several studies have tried to
identify microRNA signature for glioblastoma, a microRNA profile is still far from being
well-defined.
In this work the expression of 19 microRNAs (miR-7, miR-9, miR-9*, miR-10a, miR-10b, miR-
17, miR-20a, miR-21, miR-26a, miR-27a, miR-31, miR-34a, miR-101, miR-137, miR-182, miR-
221, miR-222, miR-330, miR-519d) was evaluated in sixty formalin-fixed and paraffin-
embedded glioblastoma samples using a locked nucleic acid real-time PCR. Moreover, a
comparison of miRNA expressions was performed between primary brain neoplasias of
different grades (grades IVeI).
The analysis of 14 validated miRNA expression in the 60 glioblastomas, using three
different non-neoplastic references as controls, revealed a putative miRNA signature:
mir-10b and miR-21 were up-regulated, while miR-7, miR-31, miR-101, miR-137, miR-222
and miR-330 were down-regulated in glioblastomas. Comparing miRNA expressionicroRNA; FFPE, Formalin-Fixed and Paraffin-Embedded; qRT-LNAPCR, Real-Time Locked Nu-
ylin and Eosin; MS-qLNAPCR, Methylation Sensitive Real-Time Locked Nucleic Acid quanti-
d Nucleic Acid quantitative PCR; FC, Fold Change; WT, Wild-Type; MET, Methylated; UMET,
rimental, Diagnostic and Specialty Medicine, DIMES, University of Bologna, Anatomic Pa-
139 Bologna, Italy. Tel.: þ39 051 622 5752.
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M O L E C U L A R O N C O L O G Y 8 ( 2 0 1 4 ) 4 1 7e4 3 0418between glioblastoma group and gliomas of grades IeIII, 3 miRNAs (miR-10b, mir-34a and
miR-101) showed different regulation statuses between high-grade and low-grade tumors.
miR-10b was up-regulated in high grade and significantly down-regulated in low-grade gli-
omas, suggesting that could be a candidate for a GBM target therapy.
This study provides further data for the identification of a miRNA profile for glioblastoma
and suggests that different-grade neoplasia could be characterized by different expression
of specific miRNAs.
ª 2013 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.1. Introduction performed to evaluate microRNA expression; ii) the startingGlioblastoma (GBM) is the most frequent and malignant brain
tumor in adults. Despite progress in surgical techniques,
radiotherapy, chemotherapy and “target therapy” its prog-
nosis remains poor (Brandes et al., 2009; Clarke et al., 2010;
Louis et al., 2007). Several biomarkers have been proposed as
potentially useful parameters for prognosis, diagnosis or ther-
apy strategies. Among them are microRNAs, or miRNAs,
which are small (19e24nt) RNA strands with tissue-specific
expression patterns and which play a functional role in
several cellular processes involved in the tumorigenesis and
progression of several neoplasia (such as proliferation, inva-
sion, migration and angiogenesis). Due to their role in the
regulation of gene expression, in the last few years miRNAs
tissue-specific expression, quantification and functional anal-
ysis of miRNAs have been extensively investigated to under-
stand their peculiar involvement in cellular processes. It is
now established that each tissue has a characteristic micro-
RNA expression pattern which could be altered in association
with a number of different diseases including neoplastic
transformation (Galasso et al., 2012; Nana-Sinkam and Croce,
2013; Zhang et al., 2007). Nowadays, there are more than a
hundred ongoing trials incorporating miRNAs as biomarkers
(Nana-Sinkam and Croce, 2013). For all these reasons miRNAs
could represent important diagnostic, prognostic or predictive
target molecules in the treatment of tumors (Galasso et al.,
2012; Lawler and Chiocca, 2009; Nana-Sinkam and Croce,
2013; Zhang et al., 2007).
In the last few years, several studies have been performed
to identify a specific microRNA expression pattern of GBM
(Chan et al., 2005; Ciafre et al., 2005; Conti et al., 2009; Dong
et al., 2010; Gal et al., 2008; Godlewski et al., 2008; Guan
et al., 2010; Hua et al., 2012; Lang et al., 2012; Loftus et al.,
2012; Malzkorn et al., 2009; Niyazi et al., 2011; Rao et al.,
2010; Sasayama et al., 2009; Silber et al., 2008; Skalsky and
Cullen, 2011; Slaby et al., 2010; Srinivasan et al., 2011; Zhang
et al., 2013; Zhou et al., 2010). For example, recent works by
LeBrun and Li (2011) and Mizoguchi et al. (2012) analyzed the
results of many GBM miRNA profiling studies and underlined
the adopted techniques, the source of neoplastic specimens
and the type of non-neoplastic reference samples used in
each study. Considering all profiling data, several discrep-
ancies have been highlighted between different studies and
a specific miRNA expression signature in GBM is far from be-
ing well-defined. These discrepancies could mainly be due to
three factors in the experimental design: i) the techniquematerial; iii) the choice of reference samples used in the
analysis.
In a previous study we reported the feasibility of perform-
ing miRNA expression analysis using a real-time locked
nucleic acid quantitative PCR (qRT-LNAPCR) starting from
either fresh/frozen or formalin-fixed and paraffin-embedded
(FFPE) GBM specimens (de Biase et al., 2012). FFPE-dissected
specimens were chosen as the most reliable material with
which to perform a miRNA profiling study. In fact, starting
from FFPE samples, a neoplastic cells enrichment step (micro-
or macro-dissection) was feasible, FFPE samples could be
easily retrieved from the archives of the Department of Pa-
thology and furthermore the obtained results displayed good
correlation values between miRNA expression and the corre-
sponding fresh/frozen material (de Biase et al., 2012). We
have also shown that it is more advisable to compare miRNA
expression data within similar experimental conditions
because of the discrepancies observed among GBM miRNA
profiles obtained using different non-neoplastic brain refer-
ences (Visani et al., 2012).
Keeping in mind both the above considerations and the
discrepant results sometimes encountered in literature be-
tween GBM miRNAs expression studies, in this study we
validated the expression of 19 microRNAs in a group of
GBM and described the signature of checked miRNAs, using
three different non-neoplastic brain controls starting from
FFPE tumor samples. Furthermore, we evaluated possible
correlation between miRNA expression and methylation
status of MGMT promoter and the putative targets of
deregulated miRNAs. Moreover, we characterized gliomas
of grades IeIII for the same panel of validated miRNAs to
evaluate if some of them could be associated to a specific
grade of malignancy.2. Materials and methods
2.1. Statement of ethics
The study was approved by Ethics Committee of Azienda
Sanitaria Locale di Bologna (number of study 08075, protocol
number 139/CE of 5th February 2009, Bologna, Italy). All pa-
tients signed a written consent for molecular analysis and
anonymous data publication for scientific studies, and all in-
formation regarding the human material used in this study
was managed using anonymous numerical codes.
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Sixty cases of primary GBM were collected for miRNA expres-
sion analysis from cases retrieved in 2009e2010 at Bellaria
(Institute of Anatomic Pathology, Bologna, Italy) and Bufalini
(Institute of Anatomic Pathology, Cesena, Italy) Hospitals,
within the PERNO (Progetto Emiliano-Romagnolo di Neuro-
Oncologia) project. Inclusion criteria were: i) primary brain tu-
mors; ii) a cryostat section evaluated by a pathologist (GM or
SC); iii) subjects had not undergone neoadjuvant therapy
before surgery; iv) subjects resident in Emilia-Romagna re-
gion. The patients included were 34 males and 26 females,
aged from 41 to 78 years (mean 62.3 yrs) (Table 1). All 60 sam-
ples were diagnosed as GBM according to the 2007 WHO
criteria (Louis et al., 2007). Thirty of these 60 cases were previ-
ously analyzed for the 19 miRNAs and represented our
training set (Visani et al., 2012) (Table 1). The 30 primary
GBM belonged to testing set were 20 males and 10 females,
aged from 41 to 78 years (mean age 61.7 yrs) (Table 1).
The following primary brain tumors were also selected: 15
grade III (2 anaplastic ependymomas, 7 anaplastic oligoden-
drogliomas, 3 anaplastic astrocytomas, 3 anaplastic oligoas-
trocytomas; 10 males and 5 females, aged 30e74 years,
mean 50.7 yrs), 15 grade II (2 ependymomas, 7 oligodendro-
gliomas, 1 pleomorphic xanthoastrocytoma, 1 diffuse astrocy-
toma and 4 neurocytomas; 11 males and 4 females, aged
21e74 years, mean 42.8 yrs) and 15 grade I (4 pilocytic astrocy-
tomas and 11 gangliogliomas; 6 males and 9 females, aged
2e23 years, mean 20.8 yrs). All samples were diagnosed ac-
cording to the 2007 WHO criteria (Louis et al., 2007) (Table 1).Table 1 e Histological classification, age and sex of the analyzed
tumor samples.
Grade tumor groups N. Of
cases
Age
(mean yrs)
Sex
M F
Grade IV (GBM) 60 41e78 (62.3) 34 26
Training set 30 42e75 (63.3)a 14 16
Testing set 30 41e78 (61.7)a 20 10
Grade III 15 30e74 (50.7) 10 5
Anaplastic ependymomas 2
Anaplastic
oligodendrogliomas
7
Anaplastic astrocytomas 3
Anaplastic
oligoastrocytomas
3
Grade II gliomas 15 21e74 (42.8) 11 4
Ependymomas 2
Oligodendrogliomas 7
Pleomorphic
xanthoastrocytoma
1
Diffuse astrocytoma 1
Neurocytomas 4
Grade I gliomas 15 2e23 (20.8) 6 9
Pilocytic astrocytomas 4
Gangliogliomas 11
M, Male; F, Female.
a No statistically significant differences were observed between
training and testing set (p= 0.6013, unpaired t-test).2.2.2. Non-neoplastic references
Fifteen “normal” tissues, adjacent to the tumor (8 males and 7
females, aged 50e75 years, mean 62.7 yrs), at a distance be-
tween 1 and 2 cm from themargin of 15 GBMs, were retrieved.
Fifteen polar temporal cortical FFPE specimens, removed in
patients submitted to surgery for drug-resistant epilepsy,
were randomly selected from the archives of the Anatomic Pa-
thology division of Bellaria Hospital (7 males and 8 females,
aged 25e52 years, mean 39.7 yrs). Additionally, the First-
Choice Human Brain Reference RNA was utilized (Ambion,
Austin, TX, U.S.A).
2.3. Nucleic acid extractions
The haematoxylin and eosin (H&E) sections from FFPE speci-
mens were reviewed by a pathologist (GM) to select the
more informative block. One 10 mm-thick and four 20 mm-thick
sections were cut, followed by one H&E control slide, for DNA
and total RNA extractions respectively. The tumor area
selected for the analysis was marked on the H&E section to
ensure, whenever possible, greater than 90% content of
neoplastic cells (avoiding necrosis and lymphocytes). Each
section was manually dissected according to the selected
area. DNA was extracted using QuickExtract FFPE DNA
Extraction Kit (Epicentre, Madison, WI, U.S.A.). miRNAs were
extracted using RecoverAll Total Nucleic Acid Isolation kit
(Ambion, Austin, TX, U.S.A.), according to manufacturer’s in-
structions. SmallRNAs were quantified and cDNA obtained
as previously described (de Biase et al., 2012; Visani et al.,
2012).
2.4. MicroRNAs analysis
19 miRNAs (miR-7, miR-9, miR-9*, miR-10a, miR-10b, miR-17,
miR-20a, miR-21, miR-26a, miR-27a, miR-31, miR-34a, miR-
101, miR-137, miR-182, miR-221, miR-222, miR-330, miR-
519d), were selected for analysis, according to their role in
cancer and data published in literature previous to the begin-
ning of the study (de Biase et al., 2012; Visani et al., 2012).
Three smallRNAs (RNU49, U54, miR-103) were used as internal
controls (de Biase et al., 2012; Visani et al., 2012). The miRNA
analyses were performed using real-time PCR as previously
described (de Biase et al., 2012; Visani et al., 2012). Briefly,
RNA was retrotranscribed using the NCode miRNA First-
Strand cDNA Synthesis and qRT-PCR Kits (Invitrogen, Carls-
bad, CA, USA), and miRNA expression was evaluated on the
AB7000 machine (Applied Biosystem, Foster City, CA, USA)
performing a miRNA-specific real-time qPCR using LNA
primers (de Biase et al., 2012; Visani et al., 2012).
2.5. Validation of the 19 miRNA expression signature in
the testing set
The expression of the 19 miRNAs was evaluated in the testing
set (n ¼ 30 GBMs) and the values compared with those ob-
tained in the training group (n ¼ 30 GBMs). In order to define
expression values of the analyzed miRNAs in GBM reducing
possible biases due to reference selection, only microRNAs
with the same regulation status in at least 2 out of the 3 pro-
files in both groups were considered.
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At least 50 ng of DNAwere treated with bisulfite using the Epi-
Tect Bisulfite kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions. A Methylation Sensitive Real-
Time qPCR using LNA modified primers and beacon probes
(MS-qLNAPCR) was performed as previously described
(Morandi et al., 2010).
2.6.2. IDH1 analysis
Tumor samples were tested for the IDH1-R132H mutation us-
ing Allele-Specific Locked Nucleic Acid quantitative PCR (ASL-
NAqPCR) (Morandi et al., 2012). To put briefly, allele-specific
primers that recognized the IDH1 wild-type sequence or the
R132H mutation were designed using Primer3 software
(http://frodo.wi.mit.edu/primer3/). Both forward primers
were designed with 30-locked nucleic acid (LNA e underlined
nucleotides within the primer sequences) substitutions to
improve mismatch discrimination (Forward primer WT: 50-
TTGATCCCCATAAGCATGAC-30; Forward primer R132H: 50-
TTGATCCCCATAAGCATGAT-30; Reverse primer: 50-GTGGCA-
CGGTCTTCAGAGA-30). The analysis was performed using
FastStart Universal ProbeMasterwith ROX (Roche Applied Sci-
ence, Mannheim, Germany) on the AB7000 machine (Applied
Biosystem, Foster City, CA, USA) with the following program:
2 min at 50 C, 4 min at 95 C followed by 37 cycles of 30 s at
95 C, 30 s at 58 C and 30 s at 72 Cwith fluorescencemeasure-
ment. GelStar stain (Lonza Bioscience, Rockland, ME, USA)
was used for signal detection.2.7. Statistical analysis
Expression values and fold changes were obtained by relative
quantification and 2DDCT method (Livak and Schmittgen,
2001) using DataAssist v3.01 Tool (Applied Biosystem, Foster
City, CA, USA). The unsupervised hierarchical clustering anal-
ysis (Pearson Correlation, average linkage) was performed us-
ing the same statistical tool. Statistical analysis of miRNA
expressionwas performed using GraphPad Prism 5.0 software.
Correlation analysis between the different groups was per-
formed applying Spearman correlation test. For comparing
the expression levels of each miRNA between different
groups, ManneWhitney test was used. Gaussian distribution
was evaluated by ShapiroeWilk Test.
AmicroRNAwas considered as down-regulated with ame-
dian fold change (FC)<2.0, while a microRNAwith amedian
FC  2.0 was considered as up-regulated.
Level of significancewas p< 0.05 for all statistical analyses.
For microRNA target analyses, a statistical over-
representation test (Cho and Campbell, 2000) was performed
using PANTHER web tool (http://www.pantherdb.org/tools/
uploadFiles.jsp). The list of target genes was compared to a
reference list to statistically determine over- or under-repre-
sentation of PANTHER classification categories. p-values
were calculated with Bonferroni correction; a cut-off of 0.05
was considered to estimate if a specific PANTHER category
was over- or under-represented in a statistically significant
way.2.8. Bioinformatic prediction of microRNA targets
The experimentally-validated targets of microRNA which
were significantly deregulated in the GBM profile were identi-
fied using three different online tools: miRecords (http://mire-
cords.umn.edu/miRecords/) (Xiao et al., 2009), miRTarBase
(http://mirtarbase.mbc.nctu.edu.tw) (Hsu et al., 2011) and
miRWalk (http://www.umm.uni-heidelberg.de/apps/zmf/
mirwalk) (Dweep et al., 2011). The latest releases of miRecords
(http://mirecords.umn.edu/miRecords/download.php,
updated onNovember 25th, 2010) andmiRTarBase (http://mir-
tarbase.mbc.nctu.edu.tw/php/download.php, “hsa MTI.xls”
file, release 3.5 of November 1st, 2012) were downloaded and
only microRNAs of interest were selected. The list of selected
microRNAs was uploaded on miRWalk “Validated target(gene)
of mirna search” section (http://www.umm.uni-heidelberg.de/
apps/zmf/mirwalk/mirnatargetpub.html, updated on March
11th, 2011) to obtain the list of experimentally-validated tar-
gets relative to each microRNAs of interest. Only targets
identified by all 3 prediction tools were then considered. Tar-
gets were analyzed and grouped according to their molecular
functions, biological process involvement and pathways clas-
sification, using the PANTHER web tool (http://www.pan-
therdb.org/) (Mi et al., 2013).3. Results
3.1. Validation of the 19 miRNA expression signature in
the testing set
Considering that microRNA was considered as down-
regulated with a median fold change (FC) < 2.0, while a
microRNA with a median FC  2.0 was considered as up-
regulated, the expression status of the 19 miRNAs in the
testing set (n ¼ 30) was compared with those of training group
(Table 2). According to this comparison, 14 miRNAs (miR-7,
miR-9*, miR-10a, miR-10b, miR-17, miR-21, miR-31, miR-34a,
miR-101, miR-137, miR-182, miR-221, miR-222 and miR-330)
showed the same regulation status between the two groups.
Only these 14 miRNAs were then considered for further
analysis.
3.2. Expression signature of the 14 validated miRNAs in
GBMs
Three different profiles were obtained comparing the 14 vali-
dated miRNAs in the entire cohort of 60 GBMs toward the
three different non-neoplastic control groups (normal tissues
adjacent to the tumor, epileptic specimens, and a commercial
reference). The median expression values of the 14 miRNAs in
the GBMs are shown in Suppl. Table 1. 6 miRNAs (miR-7, miR-
31, miR-101, miR-137, miR-222 and miR-330) were down-
regulated (Table 3, Suppl. Table 1). All miRNAs with a
FC < 2 were down-regulated in at least 50% of analyzed glio-
blastoma (Table 3, Suppl. Table 1).
Two microRNAs (miR-10b and miR-21) were up-regulated
in GBM group (Table 3, Suppl. Table 1). All miRNAs with a
FC  2 were also up-regulated in at least 50% of analyzed
GBM cases (Table 3, Suppl. Table 1).
Table 2 e Validation of the 19 miRNA expression signature in the testing set.
miR: miRNA; Ref: Ambion commercial reference; Ep: Epileptic control group; N-Ad: Normal. Adjacent the tumor group, =: not deregulated. 
a Consensus: miRNAs status in at least 2 profiles obtained with different non-neoplastic references. 
b microRNAs with the sameregulation status in training and testing set.
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andmiR-221) showed expression levels that were within the 2
fold cut-off and for this reason were considered to not be
deregulated (Suppl. Table 1).
The power of the study was calculated considering 70% of
GBM deregulated for validated miRNAs and hypothesizing to
observe at least 85% of cases with these miRNAs deregulated
in our final cohort of 60 GBMs. According to these parameters
the power of the study was 0.77.
An unsupervised hierarchical cluster showed that consid-
ering these 14 miRNAs, GBM clustered together if compared
with to non-neoplastic references (Suppl. Figure 1).
Correlation between the GBM miRNA signatures obtained
with the three non-neoplastic references were evaluated us-
ing the Spearman correlation test (Table 4). A high correlation
(>0.65) value (r ¼ 0.859 or r ¼ 0.899) was observed in all the
comparisons (Table 4). Expression values obtained using com-
mercial reference and adjacent to the tumor samples as non-
neoplastic controls showed the higher number of miRNAs
(n ¼ 11) with the same regulation status (Table 4, Suppl.
Table 1).3.3. Comparison between MGMT methylated and
unmethylated GBM samples
Twenty-seven out of 59 analyzed cases (45.8%) showed
methylation of the MGMT promoter. All cases were wild-
type for IDH1, supporting the classification of “primary GBM”
(Yan et al., 2009) (Table 5). In one case, MGMT and IDH1 anal-
ysis were not evaluable, probably due to poor quality of
extracted DNA.Considering the variation of expression of the 14 miRNAs
validated in GBM profiles, an unsupervised hierarchical clus-
tering analysis was performed to compare MGMT methylated
(MET, n ¼ 27) and unmethylated (UMET, n ¼ 32) samples. The
results indicated that there was not a significant correlation
between methylation status of MGMT promoter and micro-
RNA expression: considering this subset of microRNAs,
METeGBM and UMETeGBM groups did not show a clear clus-
terization, regardless of the selected non-neoplastic reference
(Suppl. Figure 1). Moreover, the median expression values for
each miRNA showed no differences between METeGBM and
UMETeGBM groups irrespective of the control groups used
(data not shown). 12miRNAs showed no differences in regula-
tion status between METeGBM and UMETeGBM groups.
MicroRNA-182 was up in UMETeGBM samples but not deregu-
lated in METeGBM; miR-221 was down-regulated in
UMETeGBM but not deregulated in METeGBM (data not
shown).3.4. Analysis of putative microRNA targets
To further investigate the biological relevance of the deter-
mined GBM miRNA profile, we looked for the known targets
of the 8 significantly deregulated microRNAs (Table 3). The
analysis was focused on the research of targets experimen-
tally validated in previously published studies. Among avail-
able bioinformatics tools online, miRecords, miRTarBase and
miRWalk were used. Considering the 8 microRNAs, 81 vali-
dated targets on miRecords (http://mirecords.biolead.org/)
and 174 on miRTarBase (http://mirtarbase.mbc.nctu.edu.tw/)
were found, noting that both tools consider manually-
Table 3 e miRNAs up- or down-regulated in GBM in at least 2 profiles obtained with different non-neoplastic references.
Status miRNA Non-neoplastic reference Median fold change of GBM group vs
Refa Epa N-Ada
Up-regulated miR-10b Ref, Ep 2.343 (36/60) 3.947 (44/60) ¼
miR-21 Ref, Ep, N-Ad 6.506 (51/60) 9.462 (57/60) 6.415 (52/60)
Down-regulated miR-7 Ref, Ep, N-Ad 23.641 (57/60) 50.633 (57/60) 15.723 (53/60)
miR-31 Ref, N-Ad 14.265 (54/60) ¼ 3.726 (43/60)
miR-101 Ref, Ep 2.550 (44/60) 2.750 (46/60) ¼
miR-137 Ref, Ep, N-Ad 10.428 (59/60) 17.857 (60/60) 6.215 (54/60)
miR-222 Ref, Ep, N-Ad 2.186 (33/60) 14.327 (57/60) 11.287 (56/60)
miR-330 Ep, N-Ad ¼ 5.373 (50/60) 4.354 (50/60)
miR: miRNA; Ref: Ambion commercial reference; EpEpileptic control group; N-Ad: Normal Adjacent the tumor group, ¼: not deregulated.
a Number of GBMs which shared the same deregulation status are indicated between brackets.
Table 4 e Spearman correlation ratio between miRNA expression
values in GBM obtained using the three different non-neoplastic
references.
GBM vs N-Ad GBM vs Ref GBM vs Ep
GBM vs N-Ad / 0.859 (11/14) 0.899 (8/14)
GBM vs Ref 0.859 (11/14) / 0.899 (9/14)
GBM vs Ep 0.899 (8/14) 0.899 (9/14) /
Between brackets the number of miRNAs with the same regulation
status. GBM: glioblastoma; Ref: Ambion commercial reference; Ep:
Epileptic group; N-Ad: Normal Adjacent the tumor group. p<0.0001.
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surveying. Using miRWalk (http://www.umm.uni-heidel-
berg.de/apps/zmf/mirwalk/), based on automated text-
mining search, 560 targets were found. Combining these re-
sults, 46 genes were found in common to the three target pre-
diction databases (Suppl. Table 2). This gene list was entered
into the PANTHER database in order to identify significantly
over- and under-represented pathways, molecular functions
and biological processes, in comparison with a reference list
(the default Homo Sapiens Whole Genome list was selected)
(Table 6). From the initial list of 46 genes, PANTHER was un-
able to map the gene KLF4. For this reason all analyses were
performed on a total of 45 gene targets. In Table 6, statistically
significant ( p < 0.05) pathways, molecular function classes
and biological processes relevant to the 45 gene targets were
listed. In all cases, a statistically significant over-
representation of the number of target genes per category
was observed.Table 5 eMGMT and IDH1 status of analyzed GBMs.
Groups Methylated (%) Unmet
Training (n ¼ 30) 14 (46.7) 16
Testing (n ¼ 29)a 13 (44.8) 16
TOTAL GBM (n [ 59)a 27 (45.8) 32
a In one case MGMT and IDH1 analysis were not evaluable, probably d
observed between training and testing groups for MGMT methylation
(p=1.000, Fisher’s exact test).3.5. MicroRNA expression analysis in grades IeIII brain
tumors
To evaluate possible differences in miRNA expression associ-
ated with different grade of malignancy, we further analyzed
the miRNA profiles in grades IeIII brain tumors (Suppl. Table
3). Considering that normal tissue adjacent to the tumor tis-
sues were not available for grades IeIII brain tumors, Ambion
and epileptic tissue groups were used for the analysis of miR-
NAs profile in these samples (Table 7). For this reason, we
focused our attention on the 9 miRNAs with the same GBM
expression profile with commercial and epileptic control
groups (miR-7, miR-9*, miR-10b, miR-17, miR-21, miR-34a,
miR-101, miR-137 and miR-222) (Suppl. Table 1). As happened
for GBM analysis, the up- (FC  2) or down-regulated (FC < 2)
miRNAswere deregulated in at least the 50% of analyzed sam-
ples (Suppl. Table 3).
Grade I (Table 7, Suppl. Table 3): miR-7, miR-10b, miR-137 and
miR-222 were observed as down-regulated (miR-222 only ac-
cording to the epileptic tissues); miR-21 and miR-34a were
up-regulated.
Grade II (Table 7, Suppl. Table 3): miR-7, miR-10b, miR-137 and
miR-222 were observed as down-regulated (miR-10b only
considering the commercial reference); miR-34a was up-
regulated.
Grade III (Table 7, Suppl. Table 3): miR-7, miR-101, miR-137 and
miR-22 were down-regulated; miR-10b and miR-21 were up-
regulated (miR-21 only against epileptic tissues).
Spearman correlation between the four tumor groups
(grades IVeI) showed a high (>0.65) correlation valuehylated (%) IDH1 wt (%) IDH1-R132H (%)
(53.3) 30 (100) 0 (0)
(55.2) 29 (100) 0 (0)
(54.2) 59 (100) 0 (0)
ue to poor quality of extracted DNA. No statistical differences were
status (p=1.000, Fisher’s exact test) and IDH1 mutational status
Table 6 e PANTHER over-representation analysis of target genes list.
PANTHER classification category Number of genes Over-/under-
represented
(þ/)
p-value % of target
listd
Reference
lista
Target
listb
Expectedc
Pathways
Insulin/IGF pathway-MAPKK/MAP kinase cascade 38 4 0.09 þ 3.23E-04 8.89
Angiogenesis 185 6 0.42 þ 6.63E-04 13.33
Interleukin signaling pathway 112 5 0.25 þ 9.88E-04 11.11
Gonadotropin-releasing hormone receptor pathway 282 6 0.63 þ 7.07E-03 13.33
Insulin/IGF pathway-PKB signaling cascade 38 3 0.09 þ 1.62E-02 6.67
Molecular functions
Transmembrane receptor protein kinase activity 120 5 0.27 þ 1.16E-03 11.11
Protein kinase activity 500 8 1.12 þ 2.14E-03 17.78
Kinase activity 664 8 1.49 þ 1.58E-02 17.78
Transmembrane receptor protein serine/
threonine kinase activity
52 3 0.12 þ 3.42E-02 6.67
Biological Processes
Protein amino acid phosphorylation 654 10 1.47 þ 2.66E-04 22.22
Cellular process 6072 29 13.66 þ 4.24E-04 64.44
Signal transduction 4019 22 9.04 þ 2.49E-03 48.89
Cell communication 4224 22 9.50 þ 5.65E-03 48.89
Transmembrane receptor protein tyrosine kinase
signaling pathway
295 6 0.66 þ 8.76E-03 13.33
MAPKKK cascade 454 7 1.02 þ 1.13E-02 15.56
Protein modification process 1330 11 2.99 þ 2.34E-02 24.44
Cell cycle 1602 12 3.60 þ 2.78E-02 26.67
Pathways, molecular function classes and biological processes resulted significantly over or under represented by 46 gene targets.
a Number of genes in the reference list that map to this PANTHER classification category.
b Number of genes in the target genes list that map to this PANTHER classification category.
c Expected value is the number of genes that could be expected in target genes list for this PANTHER category based on the reference list.
d Percentage of genes in the target list out of the total considered genes in PANTHER (n=45). P-values are determined by binomial statistics with
Bonferroni correction: a p-value cut-off of 0.05 was considered.
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considering the Ambion commercial reference; using the
epileptic tissues as controls the highest values were observed
and between high-grade gliomas (grades IV and III) (r¼ 0.8833)
and between low-grade gliomas (r ¼ 0.9333) (Suppl. Table 4).
An unsupervised hierarchical clustering analysis showed
that there was not a distinct clustering between different-
grade gliomas, both using Ambion commercial reference or
epileptic group as controls (data not shown).
3.6. Comparing microRNA expression analysis between
grades IeIV brain tumors
The different regulation statuses of miRNAs among the four
tumor groups were evaluated. miR-9* and miR-17 were not
deregulated in any analyzed profiles (Table 7).
3 microRNAs (miR-10b, miR-34a, miR-101) shared the same
deregulation status in high-grade gliomas (grades III and IV):
miR-34a was not deregulated in high-grade gliomas but was
up-regulated in low-grade (grades I and II) tumors (Figures 1
and 2 and Table 7); miR-101 was down-regulated in high grade
(III and IV) but not in low-grade (I and II) gliomas (Figures 1 and
2 and Table 7); miR-10b was up-regulated in high-grade gli-
omas (III and IV) and meanwhile was significantly down-
regulated in low-grade (I and II) brain tumors ( p < 0.001)
(Figures 1 and 2 and Table 7). This last microRNA was down-
regulated or not deregulated in grade II depending on the
non-neoplastic reference (Figures 1 and 2 and Table 7).3 microRNAs (miR-7, miR-137 and miR-222) were down-
regulated in all glioma groups even with observed significant
differences in expression levels (e.g. between GBM and grade
II for miR-7 e p < 0.01, or between GBM and grade I for miR-
137 e p < 0.001, Figures 1 and 2 and Table 7). MicroRNA-222
was down-regulated or not deregulated in grade I
depending on the non-neoplastic reference (Figures 1 and 2
and Table 7).
miR-21 was up-regulated in grade IV and in grade I tumors,
but it was not deregulated in those of grade II (Figures 1 and 2
and Table 7). In grade III, miR-21 showed up-regulation only
when compared with the epileptic reference (Figures 1 and 2
and Table 7).4. Discussion
Bearing in mind that in GBM the surgery, radio- and chemo-
therapies are not enough to combat tumor progression and
to ensure a hopeful outcome, the identification of a specific
pattern of expression of miRNAs in GBM could provide an
important boost in prognosis definition and in new target
therapy strategies. Presently, severalmiRNA profiles are avail-
able for GBM (Chan et al., 2005; Ciafre et al., 2005; Conti et al.,
2009; Dong et al., 2010; Gal et al., 2008; Godlewski et al., 2008;
Guan et al., 2010; Hua et al., 2012; Lang et al., 2012; Loftus
et al., 2012; Malzkorn et al., 2009; Niyazi et al., 2011; Rao
et al., 2010; Sasayama et al., 2009; Silber et al., 2008; Skalsky
Table 7 eMicroRNA expression status in different-grade tumor groups.
Ambion commercial reference/epileptic group were used as non-neoplastic controls. 
a p-value is calculated according to Mann-Whitney test versus grade IV profile.
b Using the 2 different references, commercial reference/epileptic tissues, a different regulation status was observed. 
UP: up-regulated; DOWN: down-regulated; =: not deregulated; ns: not statistically significant. 
* p<0.05, ** p<0.01, *** p<0.001.
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Zhang et al., 2013; Zhou et al., 2010) and a small subset of
consistently deregulated miRNAs was further functionally
characterized for their activities and downstream targets
possibly involved in the tumor (Chen et al., 2008; Huse et al.,
2009; Kefas et al., 2008; Li et al., 2011; Sasayama et al., 2009;
Smits et al., 2010). However, due to several differences in the
study designs, a clear miRNA profile for GBM has not been
established yet. Considering the data previously obtained by
our group (de Biase et al., 2012; Visani et al., 2012), in this study
the expression of 19 miRNAs in GBM was analyzed, starting
from FFPE-dissected samples to ensure a good enrichment in
neoplastic cells (de Biase et al., 2012). Three different non-
neoplastic references (Visani et al., 2012) were enrolled for
the analysis, to verify if different controls could influence
GBM microRNAs expression values. Fourteen out of these 19
miRNAs showed the same deregulation status between
training and testing sets and for this reason considered for
further analysis.
According to adopted non-neoplastic references, differ-
ences in the median expression values of the 14 validated
microRNAs in GBM were observed. Furthermore, different
fold-change values were observed even in those miRNAs
with the same regulation status between all three profiles
(e.g. miR-7, miR-137).
To better define a GBMmicroRNA signature, only validated
microRNAs deregulated in at least 2 out of the 3 profiles ob-
tained were considered. According to our results, 2 miRNAs
(miR-10b and miR-21) were up-regulated and 6 miRNAs
(miR-7, miR-31, miR-101, miR-137, miR-222 and miR-330)
were down-regulated in group of 60 GBMs.The microRNA GBM signature found in the present series
was in accordance with profiling data previously reported in
literature, except for miR-222 that was down-regulated in
our series. Although miR-221 and miR-222 are encoded in
the same genomic cluster on the X chromosome (http://
www.ncbi.nlm.nih.gov/gene/, Genes ID: 407006 and 407007),
miR-221, differently than miR-222, was not deregulated.
Several studies reported an up-regulation ofmiR-221/222 clus-
ter in GBM (Ciafre et al., 2005; Quintavalle et al., 2012; Zhang
et al., 2010). Quintavalle et al. (2012) and Zhang et al. (2010)
assessed the up-regulation of miR-222 in GBM cell lines in
comparison with non-tumorigenic cell line or the commercial
reference. On the contrary, in the present study, we evaluated
the regulation of miRNAs in surgical GBM specimens and not
in cell lines by using three different non-neoplastic controls.
Ciafre et al. (2005) analyzed miR-221 in fresh/frozen samples
andmiR-222 in cell lines. In these situations, the discrepancies
observedwith our data could be due to the differences in start-
ing material used for establishing microRNA expression.
The down-regulation of miR-221 and miR-222 status was
previously observed by Slaby et al. and Lakomy et al. using
stem-loop RT-PCR in FFPE-dissected GBMs (ensuring >90% of
tumor cells) in comparison to non-malignant brain tissues,
derived from areas surrounding arteriovenous malformation
(AVM) or from commercial reference (Slaby et al., 2010;
Lakomy et al., 2011). Slaby et al. (2010) explained this down-
regulation was due to the choice of normal brain samples
that could lead to discrepant results with data obtained in
other studies.
The differences observed in the expression of miRNAs
belonging to the same genomic cluster (miR-221 and miR-
Figure 1 e Differences in miRNA expressions among the 4 different-grade tumor groups evaluated using the Ambion commercial reference as
control. Box plots show microRNAs different between GBM Group (grade IV) and the other 3 tumor groups. Y-axis indicates the microRNA
Log10 expression level: “Up” and “Down” lines highlight the cut-off of 2 fold change used to consider a microRNA as deregulated. In bold the up-
or down-regulated median FC values. Bars mean minimum and maximum values of miRNAs. *p< 0.05, **p< 0.01, ***p< 0.001 according to
ManneWhitney test. FC: median Fold Change.
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described, for example, by Davis et al. (2009).
According to our panel, only 2 miRNAs (miR-182 and miR-
221) showed a different regulation status betweenmethylated
and unmethylated samples. MicroRNA-221 was previously
described as mechanism of post-transcriptional regulation
of MGMT (Quintavalle et al., 2013). On the contrary, to the
best of our knowledge, a possible correlation between miR-
182 and MGMT methylation status has not been previously
described in literature.
Taking into account the 8 microRNAs (miR-7, miR-10b,
miR-21, miR-31, miR-101, miR-137, miR-222 and miR-330)
showing a deregulation in GBMs, a preliminary analysisof their experimentally-validated targets was performed.
Forty-six targets, shared by three bioinformatics tools,
were further analyzed for their molecular function and
pathway involvement: interleukin signaling, insulin/IGF
pathway-MAPKK/MAPK cascade, gonadotropin-releasing
hormone receptor (GNRHR), angiogenesis and Insulin/IGF-
PKB pathways were significantly represented by this list
of targets and previous studies have demonstrated their
decisive role in GBM pathogenesis (Bulnes et al., 2012; de
la Iglesia et al., 2008; Ermoian et al., 2002; Low et al.,
2008; Montagnani Marelli et al., 2009; Nakada et al., 2011;
Trojan et al., 2007; van Groeninghen et al., 1998; Wang
et al., 2012).
Figure 2 e Differences in miRNA expressions among the 4 different-grade tumor groups was evaluated using the epileptic group as control. Box
plots show microRNAs different between GBM Group (grade IV) and the other 3 tumor groups. Y-axis indicates the microRNA Log10 expression
level: “Up” and “Down” lines highlight the cut-off of 2 fold change used to consider a microRNA as deregulated. In bold are the up- or down-
regulated median FC values. Bars mean minimum and maximum values of miRNAs. *p< 0.05, **p< 0.01, ***p< 0.001 according to
ManneWhitney test. FC: median Fold Change.
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miR-17, miR-21, miR-34a, miR-101, miR-137, miR-222) with
consistent regulation status in GBM using Ambion reference
or epileptic tissues, was also investigated in lower grade tu-
mors (grades IeIII), to evaluate if there were relevant differ-
ences associated with different grades of malignancy. Only 3
microRNAs (miR-7, miR-137 and miR-222) showed the same
deregulation status in all four tumor grades. Nonetheless,
some significant differences in miRNAs expression levels
were observed between the groups.
In spite of the power of the study below 0.8 (0.77) and the
awareness that a higher number of GBM should be preferable
for more accurate results, it should be considered thedistinctiveness and uniformity of our cohort, composed of
60 highly selected GBM. In fact all patients were resident in
the same geographical region (Emilia-Romagna) and were
surged by the same surgical teams, all diagnoses were ob-
tained with a consensus between neuropathologists and all
GBM were primary tumors. All these criteria were chosen for
having a homogeneous cohort of specimens and limiting
bias of results due to study design.
The unsupervised hierarchical clustering analysis showed
that there was no distinct clusterization between different-
grade gliomas. This might suggest that the entire panel of
these 9 microRNAs is unsuitable for discriminating gliomas
based on the grade of malignancy.
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status in high-grade gliomas (grades III and IV): miR-34a,
miR-101 and miR-10b. miR-34a, stable in high-grade tumors,
was on the other hand up-regulated in low-grade gliomas
(grades I and II); this miRNA was previously reported to be
down-regulated in GBMand its possible role in GBMpathogen-
esis was investigated (Genovese et al., 2012; Li et al., 2009;
Silber et al., 2012). Oncogenes like c-met, Notch1, Notch2,
CDK6, PDGFRA and SMAD4, in TGFb/SMAD pathway, were vali-
dated as targets of miR-34a and they were effectively over-
expressed in GBM (Genovese et al., 2012; Li et al., 2009; Silber
et al., 2012). Although miR-34a was not deregulated in our
high-grade glioma groups, it showed an up-regulation in
low-grade tumors, suggesting a possible association between
miR-34a loss of expression and pathogenesis of high-grade
glial neoplasias.
miR-101 was down-regulated in high grade but not in low-
grade gliomas, and this result is in accord with previously
published studies (Silber et al., 2008; Smits et al., 2010). In
particular, we discovered that miR-101 down-regulation is
present only in association with high-grade malignancy.
Smits et al. (2010) have previously demonstrated one possible
role ofmiR-101 in GBMprogression; they obtained lower levels
of miR-101 in comparison with grades II and III gliomas and
they reported the association with over-expression of miR-
101 target EZH2, which influences proliferation, invasion and
angiogenesis.
miR-10bwas up-regulated in high-grade gliomaswhilewas
significantly down-regulated in low grade ones. The data con-
cerning GBM is in-line with results previously published by
other studies (Ciafre et al., 2005; Gabriely et al., 2010;
Sasayama et al., 2009; Silber et al., 2008). In particular,
Gabriely et al. (2010) demonstrated the role of miRNA-10b in
cell proliferation and in cell cycle regulation by targeting Bim
(a pro-apoptotic factor), p16/CDKN2A and p21/CDKN1B. Addi-
tionally, the studybySasayamaet al. (2009) reported that levels
of invasive factors RhoCandurokinase-typeplasminogenacti-
vator receptor (uPAR) were inversely correlated with miR-10b
expression, indicating that it might play a key role in invasion
features of gliomas. They reported that miR-10b expression
was associated with glioma grade of malignancy and its
expression was significantly lower in low-grade gliomas
compared to high-grade astrocytic tumors (Sasayama et al.,
2009). All of this data has suggested that the silencing of miR-
10b could be a potential therapeutic strategy for GBM treat-
ment. An analysis of miR-10b expression in primary low-
grade gliomas and in corresponding secondary GBM lesions
could be useful to evaluate a possible correlation with tumor
progression. It should be considered that the present series of
low-grade gliomas were heterogeneous groups. Further
studies are necessary for determining specific differences be-
tweenGBManddifferenthistotypesof low-gradebrain tumors.
In conclusion, we determined a GBMmicroRNA profile and
performed a comparison of selected miRNAs in different-
grade gliomas. Beyond these results, one of the main conclu-
sions of our study is that GBM microRNA profiling studies
should be compared considering similar experimental condi-
tions (i.e. the number of cases analyzed, the type of selected
tissue, the non-neoplastic control chosen and the technique
adopted for microRNA expression analysis).Bearing in mind these considerations, further investiga-
tions such as extensive sequencing of miRNAs in a vast group
of GBM or the analysis of miRNA expression in low-grade pri-
mary glioma tumors and in their corresponding secondary
high-grade lesions, could be critical to discover new therapeu-
tic strategies and possible correlations with glioma
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